XW023X7
ICD-10-PCSTerminatedIntroduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
Inactive since October 1, 2026
This code is no longer billable. Claims with this code will be denied for dates of service after the inactive date.
No automated successor mapping is available. Consult the CMS transmittal or AMA CPT Assistant for replacement guidance.
This code describes the administration of a specific combination of monoclonal antibodies, tixagevimab and cilgavimab, directly into muscle tissue. This intervention is performed through the skin using a needle, without requiring an incision. It represents a novel therapeutic approach for certain conditions.
This code is used when a patient receives tixagevimab and cilgavimab via intramuscular injection for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals or those for whom COVID-19 vaccination is not recommended. It applies to inpatient encounters where this specific monoclonal antibody combination is administered.
AI-generated reference. Verify against official guidelines.
+5 more in this category
Code History
This code is no longer billable. Check the replacement code if applicable.
Change History